PloS one · 2025
Osteopontin, kidney injury molecule-1, and fetuin-A as prognostic markers of end-stage renal disease: A systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Welliam Yongki, Witarto Bendix Samarta, Visuddho Visuddho, Wungu Citrawati Dyah Kencono, Budiarto Raden Mohammad, Susilo Hendri, Multazam Chaq El Chaq Zamzam
Аннотация
BACKGROUND: The global prevalence of chronic kidney disease (CKD) as a major renal disease is increasing rapidly. The progression of CKD may lead to end-stage renal disease (ESRD). Current diagnostic and prognostic methods still have some limitations. This study aims to evaluate the potential and predictive ability of Osteopontin (OPN), Kidney injury molecule-1 (KIM-1), and Fetuin-A on the incidence of ESRD in CKD patients.
METHODS: A systematic review and meta-analysis were carried out based on the PRISMA guideline on registered databases for studies published up to December 21, 2023. The concentrations of each marker were then reported in pooled standardized mean difference (SMD) and hazard ratio (HR). Subgroup analysis was performed based on age, location, and KIM-1 specimen.
RESULTS: We included 21 studies involving 15,983 patients. Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59-9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50-2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 - -0.26, p = 0.01) were significant in CKD patients with ESRD. Chronic kidney disease patients with increased KIM-1 levels showed 1.13 times increased risk of ESRD (HR = 1.13, 95% CI = 1.10-1.17, p <0.0001). Subgroup analysis showed that increased KIM-1 in urine or blood was strongly associated with ESRD, and decreased Fetuin-A levels in Asians had a significant association with the incidence of ESRD.
CONCLUSION: Osteopontin, KIM-1, and Fetuin-A significantly reflect ESRD in CKD patients, making them potential prognostic indicators.
METHODS: A systematic review and meta-analysis were carried out based on the PRISMA guideline on registered databases for studies published up to December 21, 2023. The concentrations of each marker were then reported in pooled standardized mean difference (SMD) and hazard ratio (HR). Subgroup analysis was performed based on age, location, and KIM-1 specimen.
RESULTS: We included 21 studies involving 15,983 patients. Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59-9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50-2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 - -0.26, p = 0.01) were significant in CKD patients with ESRD. Chronic kidney disease patients with increased KIM-1 levels showed 1.13 times increased risk of ESRD (HR = 1.13, 95% CI = 1.10-1.17, p <0.0001). Subgroup analysis showed that increased KIM-1 in urine or blood was strongly associated with ESRD, and decreased Fetuin-A levels in Asians had a significant association with the incidence of ESRD.
CONCLUSION: Osteopontin, KIM-1, and Fetuin-A significantly reflect ESRD in CKD patients, making them potential prognostic indicators.